Discovery & Clinical Trials
News and Publications
Discovering, developing & commercializing broad-spectrum antivirals
Dedicated to preventing and treating life- threatening viral infections
Innovation to address high unmet medical needs
Welcome to Chimerix
(NASDAQ: CMRX) Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need.
SUPPRESS Phase 3 Trial
SUPPRESS is designed to demonstrate the efficacy and safety of brincidofovir for the prevention of CMV infection versus a placebo control, as no therapy is currently approved for the prevention of CMV in HCT recipients.
Jan 12 2015
Chimerix Receives Notice of Allowance for Brincidofovir Composition of Matter Patent Extending Exclusivity to 2034
Jan 08 2015
Chimerix Provides Update on Brincidofovir Pivotal Phase 3 AdVise Trial for the Treatment of Adenovirus
Jan 07 2015
Chimerix to Present at the 33rd Annual J.P. Morgan Healthcare Conference